Frontlight ResearchEarly access
Chronic lymphocytic leukaemia trials in Canada
20 of 23 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Where
- Halifax, Montreal, Oshawa, Ottawa, Regina, Saint John, Vancouver, Winnipeg
- Age
- 18 years and over
- People
- 247 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT04269902 - Phase 3Taking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Greenfield Park, Hamilton, London, Montreal, Ottawa, SaintJerome
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Greenfield Park, Kingston, Moncton, Sherbrooke
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 2Taking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Barrie, Saskatoon
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - Phase 4Not yet taking people in CanadaA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Toronto
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Calgary, Montreal, Ottawa, Toronto
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 3Taking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Calgary, Edmonton, Montreal, Ottawa, Québec, St. John's, Toronto, Vancouver, Winnipeg
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - Phase 1Taking peopleCLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
- Where
- Calgary, Ottawa, Toronto, Vancouver
- Age
- 1 year and over
- People
- 24
- Run by
- British Columbia Cancer Agency
See details and how to joinNCT06208735 - Phase 3Not yet taking people in CanadaSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Fredericton, Montreal
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - Phase 3Taking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Brampton, Kelowna, Montreal, Ottawa, Rimouski, Victoria
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - Phase 3Taking peopleSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Where
- Calgary, Halifax, Hamilton, Montreal, Québec, Toronto, Vancouver
- Age
- 18 years to 18 years
- People
- 420 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07509151 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Calgary, Edmonton, Québec, Toronto, Vancouver
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Calgary, Montreal, Toronto
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Hamilton, Montreal, Québec, Sherbrooke, Victoria
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Montreal, Québec, Winnipeg
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - Phase 3Taking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Halifax
- Age
- 18 years to 99 years
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - Phase 1Taking peopleStudy of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
- Where
- Toronto
- Age
- 18 years and over
- People
- 19
- Run by
- University Health Network, Toronto
See details and how to joinNCT05963217 - Phase 1Taking peopleStudy of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Where
- Toronto
- Age
- 18 years and over
- People
- 242 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT04260022 - Phase 1/2Taking peopleCLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
- Where
- Ottawa, Vancouver, Winnipeg
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Ottawa Hospital Research Institute
See details and how to joinNCT03765177 - Phase 2Not yet taking people in CanadaTime Restricted Eating in Haematological Malignancies
- Where
- Victoria
- Age
- 18 years to 85 years
- People
- 75
- Run by
- British Columbia Cancer Agency
See details and how to joinNCT06862323